Furthermore, to further ascertain the involvement of NF-κB signaling in ERCC6L-induced EMT, pretreatment of GC cells with helenalin (an NF-κB inhibitor) [15] resulted in blockade of the increase in ERCC6L-induced EMT, and cell growth, migration and invasion. The gene discussed is ERCC6L; the disease is gastric cancer.